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Background-—Hydralazine-isosorbide dinitrate (H-ISDN) therapy is recommended for African American patients with moderate to
severe heart failure with reduced ejection fraction (<40%) (HFrEF), but use, temporal trends, and clinical characteristics associated
with H-ISDN therapy in clinical practice are unknown.
Methods and Results-—An observational analysis of 54 622 patients admitted with HFrEF and discharged home from 207
hospitals participating in the Get With The Guidelines–Heart Failure registry from April 2008 to March 2012 was conducted to
assess prescription, trends, and predictors of use of H-ISDN among eligible patients. Among 11 185 African American patients
eligible for H-ISDN therapy, only 2500 (22.4%) received H-ISDN therapy at discharge. In the overall eligible population, 5115 of
43 498 (12.6%) received H-ISDN at discharge. Treatment rates increased over the study period from 16% to 24% among African
Americans and from 10% to 13% among the entire HFrEF population. In a multivariable model, factors associated with H-ISDN use
among the entire cohort included younger age; male sex; African American/Hispanic ethnicity; and history of diabetes,
hypertension, anemia, renal insufﬁciency, higher systolic blood pressure, and lower heart rate. In African American patients, these
factors were similar; in addition, being uninsured was associated with lower use.
Conclusions-—Overall, few potentially eligible patients with HFrEF are treated with H-ISDN, and among African-Americans fewer
than one-fourth of eligible patients received guideline-recommended H-ISDN therapy. Improved ways to facilitate use of H-ISDN
therapy in African American patients with HFrEF are needed. (J Am Heart Assoc. 2013;2:e000214 doi: 10.1161/JAHA.113.
000214)
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H
eart failure (HF) results in substantial morbidity, mor-
tality, and healthcare expenditures.
1–3 African Ameri-
cans are at increased risk for developing HF and experience
worse outcomes post-HF development.
4,5 Beyond angioten-
sin-converting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs), beta-blockers, and aldosterone
antagonists use in patients with heart failure with reduced
ejection fraction (HFrEF),
6–13 clinical trials have established
incremental beneﬁt with hydralazine-isosorbide dinitrate
(H-ISDN) therapy in African American HFrEF patients in terms
of mortality, morbidity, and quality of life. In addition, data in
non–African American HF patients with H-ISDN are encour-
aging, with proven beneﬁts in terms of remodeling and
exercise tolerance, but not on hard outcomes such as
mortality and morbidity.
14–16 Both the American College of
Cardiology/American Heart Association and Heart Failure
Society of America guidelines recommend H-ISDN as a part of
standard therapy for self-identiﬁed African American patients
with HFrEF. In addition, these guidelines also recommend
H-ISDN therapy to be considered in non–African American
patients with HFrEF who remain symptomatic despite opti-
mized standard therapy.
17,18
Despite these guideline recommendations, there are very
few contemporary studies regarding the utilization of H-ISDN
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ORIGINAL RESEARCHin real-world practice. The Get With The Guidelines–Heart
Failure (GWTG-HF) program is a national quality improvement
program designed to promote adherence to guideline-based
medical therapies.
19,20 Using data from GWTG-HF, we
conducted an analysis to examine contemporary use of
H-ISDN in the overall cohort of HFrEF patients and then
speciﬁcally in self-identiﬁed African American patients hospi-
talized with HFrEF, temporal trends in H-ISDN use over time,
and patient and hospital factors associated with H-ISDN
prescription.
Methods
Data Collection
GWTG-HF is an ongoing prospective registry and quality
improvement program initiated in January 2005 by the
American Heart Association.
19,20 Participating hospitals
include institutions from all regions of the United States
and represent community hospitals as well as tertiary-care
referral centers. The registry enrolls adults hospitalized with
new or worsening HF as the primary diagnosis or with
signiﬁcant HF symptoms that develop during the hospitaliza-
tion for which HF is the primary discharge diagnosis. Data
collected include demographic and clinical characteristics,
comorbidities, previous therapies and interventions, labora-
tory values, pharmacological and nonpharmacological inter-
ventions, contraindications to evidence-based therapies, and
in-hospital outcomes. Patient’s self-identiﬁed race (American
Indian or Alaska Native, Asian, African American or black,
Native Hawaiian or Paciﬁc Islander, white, or unable to be
determined) and ethnicity (Hispanic, yes, no, or unable to be
determined) is registered. Hospital personnel are trained to
use standardized deﬁnitions. All participating institutions are
required to comply with local regulatory and privacy guide-
lines and to obtain approval from their institutional review
boards before participation. As data are primarily collected for
quality improvement purposes, all sites are granted a waiver
for informed consent under the Common Rule. Internet-based
system checks of data quality are performed to ensure their
completeness and accuracy. Outcome Sciences, Inc (Cam-
bridge, MA), serves as the data collection and coordination
center, and the Duke Clinical Research Institute (Durham, NC)
serves as the data analysis center under an agreement to
analyze the aggregate deidentiﬁed data for research pur-
poses.
Study Population
From April 1, 2008, through March 24, 2012, 122 395
patients admitted with HF were discharged from 207
hospitals participating in the GWTG-HF program. The use of
H-ISDN prior to 2008 was collected differently and could not
be directly compared, and hence the study period was 2008
onward. The use of H-ISDN was deﬁned as patients prescribed
either (1) the ﬁxed dose combination of H-ISDN or (2)
hydralazine+any formulation of nitrates (ie, mononitrate or
dinitrate). The following groups of patients were excluded
from the study analysis: patients with missing data on
ejection fraction (n=3868) or ejection fraction >40%
(n=63 905); patients with unknown race or ethnicity
(n=2288); those with documented contraindication to H-ISDN
therapy (n=2508); those who were comfort care only
(n=2974); and those who died, left against medical advice,
transferred to another hospital, discharged to hospice, or had
missing information on discharge destination (n=2954). The
ﬁnal study population thus included 43 898 patients with
HFrEF from 195 hospitals who were discharged home without
medical contraindications to H-ISDN therapy.
Outcome and Deﬁnitions
The primary outcome was prescription rate of H-ISDN in
HFrEF patients at discharge in (1) African Americans patients
and (2) the entire study population irrespective of race/
ethnicity. We also studied the temporal trends in the use of
H-ISDN over the study period (2008–2012), variation in use of
H-ISDN across hospitals, patterns of use at various times (eg,
newly started, discontinued or continued during hospitaliza-
tion, or at discharge), and factors associated with its use.
Statistical Analysis
Data were compared between patients prescribed and not
prescribed H-ISDN using chi-square tests for categorical data
and Wilcoxon rank sum tests for continuous variables.
Percentages and means with standard deviations (SDs) were
reported for categorical and normally distributed continuous
variables, and medians with 25th and 75th percentiles were
reported for nonnormally distributed continuous variables.
Chi-square tests were used to test associations between
prescription and patient groups. Time was divided into yearly
intervals. Cochran-Mantel-Haenzel row mean scores statistics
were used to test the trend of prescription over the study
period. A multivariable logistic regression model was used to
examine factors associated with H-ISDN use among eligible
patients (in overall population as well as among African
American patients). The generalized estimating equations
approach was employed to account for within-hospital
clustering. The candidate variables in the initial models
included demographics, medical history, vital signs, insurance
status, hospital teaching status, region, and number of beds.
Also performed was a similar model including the variables
mentioned above and use of H-ISDN before admission or
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Hduring hospitalization as well. Some patient variables, includ-
ing body mass index, weight, and laboratory values and
hospital-level variables including capability of percutaneous
coronary intervention, surgery, and heart transplant had >10%
to 20% missing data and thus were not included in the
multivariate model. The patient characteristic variables
included in the model had <5% missing data, and their
missing data were imputed to median value for continuous
variables and dominant level for categorical variables. Hospi-
tal region data were complete, and there was 2% missing data
on teaching status and number of beds, and these missing
data were excluded from the multivariable analysis. All tests
were 2-sided, and because of the large cohort studied, P<0.01
was considered statistically signiﬁcant. Analysis was per-
formed using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Irrespective of race/ethnicity, overall 43 898 patients from
195 hospitals treated with HFrEF were potentially eligible for
H-ISDN therapy at discharge. Of these patients, 5515 (12.6%)
were prescribed H-ISDN. Baseline demographic and clinical
characteristics of patients stratiﬁed by prescription of H-ISDN
at the time of discharge are shown in Table 1. Patients who
received H-ISDN at discharge were younger, more likely to be
male and African American, appeared to have more advanced
disease, and were more likely to have comorbidities including
history of chronic obstructive pulmonary disease, diabetes
mellitus, hyperlipidemia, hypertension, peripheral vascular
disease, stroke, anemia, renal insufﬁciency, chronic dialysis,
lower heart rate, and higher systolic blood pressure. Even
more importantly, patients who received H-ISDN were more
likely to be treated with beta-blockers, aldosterone antago-
nists, calcium channel blockers, and diuretics and less likely
to be treated with ACEIs before admission.
H-ISDN use at the time of discharge differed by race/
ethnic group, being more frequent in African American
patients (2500 of 11 185 [22.4%] among African American
patients; 2409 of 26 922 [9.0%] among white patients, 414 of
3824 [10.8%] among Hispanic patients, and 192 of 1967
[9.8%] among other race/ethnic group patients). In the entire
cohort, the discharge prescription of H-ISDN was more
common among those patients with H-ISDN from before
admission (1469 of 1818, 80.8%). This is in comparison with
discharge prescription of H-ISDN in patients without H-ISDN
before admission (4046 of 42 080, 9.6%). In the African
American subgroup, the discharge prescription of H-ISDN was
84.6% versus 17.3% in those with versus without H-ISDN
before admission.
Table 2 shows hospital characteristics, American College
of Cardiology/American Heart Association performance mea-
sures, and GWTG-HF quality measures stratiﬁed by H-ISDN
use. Patients discharged with H-ISDN were more likely to be
treated at academic medical centers, hospitals with surgical
capabilities, and those with a greater number of beds.
At the time of discharge, the use of H-ISDN in eligible
patients varied widely by hospital. The mean rate of H-ISDN
use in 167 hospitals with ≥10 eligible patients was 12.1%,
with a median (25th, 75th percentiles) of 9.6% (4.4%, 15.1%)
(Figure 1). Among 90 hospitals with ≥10 African American
eligible patients, mean H-ISDN rate among all patients was
13.6%, with a median (25th, 75th percentiles) of 11.6% (7.7%,
17.2%) (Figure 2) and mean rate of 21.0% with a median
(25th, 75th percentiles) of 19.2% (12.1%, 26.3%) among
African American patients.
Table 3 shows the patterns of use at the time of
admission, hospitalization, and discharge. Of the patients
already on H-ISDN before hospital admission, 61.3% had
H-ISDN continued through the entire hospitalization, 19.5%
had it stopped during hospitalization but restarted at
discharge, whereas 11.6% had H-ISDN stopped at discharge.
Among African American patients on H-ISDN before hospital-
ization, 63.7% had it continued through discharge, whereas
8.9% had it discontinued at discharge. Among patients not on
H-ISDN at the time of admission, only 3.6% had H-ISDN
initiated at the time of discharge in the entire cohort; among
African American patients, this ﬁgure was 6.5%. Table 4
shows the patterns of H-ISDN use among HF patients with
documented contraindication/intolerance to ACEIs/ARBs.
The percentage of African American HFrEF patients with
documented contraindication/intolerance to ACEIs/ARBs
who were not receiving H-ISDN before hospital admission
was 85.5%. In this patient group, H-ISDN therapy was initiated
in 25.3% during hospitalization and started in another 11.8%
of patients at the time of hospital discharge.
Table 5 demonstrates independent patient and hospital
characteristics associated with H-ISDN prescription. In the
overall population, factors associated with H-ISDN use were
younger age, male sex, African American/Hispanic race, and
history of diabetes mellitus, hypertension, implantable car-
dioverter deﬁbrillator implantation, heart failure, anemia, renal
insufﬁciency, higher systolic blood pressure, and lower heart
rate. On the other hand, patients with a history of smoking
and on chronic dialysis had lower use of H-ISDN at discharge.
In African American patients, factors associated with H-ISDN
use were similar except that being uninsured was associated
with lower use, and history of chronic obstructive pulmonary
disease was associated with higher use (Table 6). Further-
more, when prior use of H-ISDN before discharge (either
before admission or during hospitalization) was included in
the model for overall population, age, history of hypertension,
and chronic dialysis were no longer signiﬁcantly associated
factors, and the strength of association decreased for those
other signiﬁcant characteristics for the overall population.
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HTable 1. Patient Characteristics by Hydralazine-Isosorbide Dinitrate Use at Hospital Discharge
Patient Characteristics
Hydralazine-Isosorbide Dinitrate Use, n (%)
Total, n=43 898 Yes, n=5515 No, n=38 383 P Value
Age (y), mean (SD) 68.3 (15.1) 65.4 (15.2) 68.7 (15.0) <0.0001
Male (%) 27 381 (62.4) 3628 (65.8) 23 753 (61.9) <0.0001
Race/ethnicity (%) <0.0001
White 26 922 (61.3) 2409 (43.7) 24 513 (63.9)
African American 11 185 (25.5) 2500 (45.3) 8685 (22.6)
Hispanic 3824 (8.7) 414 (7.5) 3410 (8.9)
Other 1967 (4.5) 192 (3.5) 1775 (4.6)
Body mass index (kg/m
2), mean (SD) 28.8 (8.1) 30.0 (8.4) 28.65 (8.0) <0.0001
Insurance (%) <0.0001
Uninsured 26 222 (5.97) 352 (6.38) 2270 (5.91)
Medicare 23 338 (53.1) 2752 (49.9) 20 586 (53.6)
Medicaid 4687 (10.7) 840 (15.2) 3847 (10.0)
Other 11 383 (25.9) 1285 (23.3) 10 098 (26.3)
Medical history (%)
Hypertension 31 702 (74.2) 4471 (82.1) 27 231 (73.1) <0.0001
Diabetes 17 627 (41.2) 2754 (50.5) 14 873 (39.9) <0.0001
Hyperlipidemia 20 585 (48.2) 2728 (50.1) 17 857 (47.9) 0.003
Atrial fibrillation 12 770 (29.9) 1434 (26.3) 11 336 (30.4) <0.0001
Atrial flutter 1065 (2.5) 150 (2.7) 015 (2.5) 0.19
COPD/asthma 11 813 (27.7) 1580 (29.0) 10 233 (27.5) 0.018
Peripheral vascular disease 4952 (11.6) 744 (13.7) 4208 (11.3) <0.0001
Coronary artery disease 21 732 (50.9) 2839 (52.1) 18 893 (50.7) 0.05
Prior myocardial infarction 10 899 (25.5) 1335 (24.5) 9564 (25.7) 0.07
Cerebrovascular disease 5760 (13.5) 871 (16.0) 4889 (13.1) <0.0001
ICD 8380 (19.6) 1380 (25.3) 7000 (18.8) <0.0001
Prior heart failure 31 266 (73.2) 4331 (79.5) 26 935 (72.2) <0.0001
Anemia 6504 (15.2) 1164 (21.3) 5340 (14.3) <0.0001
Pacemaker 6116 (14.3) 738 (13.5) 5378 (14.4) 0.08
CRT-P 360 (0.84) 43 (0.79) 317 (0.85) 0.64
CRT-D 3781 (8.9) 659 (12.1) 3122 (8.4) <0.0001
Chronic dialysis 1278 (2.9) 214 (3.9) 1064 (2.9) <0.0001
Renal insufficiency 8764 (20.5) 2085 (38.2) 6679 (17.9) <0.0001
Depression 3725 (8.7) 2085 (38.2) 6679 (17.9) <0.0001
Prior PCI 7239 (16.9) 910 (16.7) 6239 (16.9) <0.0001
Prior CABG 9842 (23.0) 1221 (22.4) 6621 (23.1) 0.24
Valvular heart disease 6870 (16.0) 832 (15.3) 6038 (16.2) 0.08
Smoking 9584 (21.8) 1214 (22.0) 8370 (21.8) 0.78
Vital signs on admission, mean (SD)
Heart rate, bpm 88 (20) 86 (19) 88 (20) <0.0001
Systolic blood pressure 136 (29) 145 (32) 134 (28) <0.0001
Continued
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over time. H-ISDN prescription increased over 4 years in the
overall population from 10.1% in 2008 to 13.3% in 2011–
2012 (P<0.0001). This trend was signiﬁcant in both African
American (16.6% to 25.0%, P<0.0001) and white (7.2% to
9.3%, P=0.0004) patients, whereas statistically nonsigniﬁcant
trends were noted between Hispanic and other race/ethnic
groups.
Discussion
Both the American College of Cardiology/American Heart
Association and the Heart Failure Society of America HF
management guidelines recommend the use of a ﬁxed-dose
combination of H-ISDN added to a standard medical regimen
for HF, including ACEIs and beta-blockers, in self-identiﬁed
African American patients with symptomatic HFrEF (class I,
level of evidence B). In addition, H-ISDN use is also
recommended in non–African American patients who remain
symptomatic on optimized medical therapy (class IIb, level of
evidence C).
7,18 In this cohort of >40 000 patients with
HFrEF, we demonstrate that <15% of the overall cohort and
<25% of the eligible African American patients were pre-
scribed H-ISDN therapy at the time of discharge. Prescription
of H-ISDN varied at discharge widely across hospitals and
according to patient characteristics.
When compared with reports from prior registries, the
ﬁndings of this study suggest higher rates of treatment with
H-ISDN. Reports from the Organized Program to Initiate
Lifesaving Treatment in Hospitalized Patients With Heart
Failure registry from 2003 to 2004 showed that only 4.5% of
African American patients and 2.6% of white patients
hospitalized with HF were discharged with prescriptions for
H-ISDN.
21 In addition, Improving Evidence-Based Care for
Heart Failure in Outpatient Cardiology Practices registry data,
which studied the use of evidence-based medical therapy in
Table 1. Continued
Patient Characteristics
Hydralazine-Isosorbide Dinitrate Use, n (%)
Total, n=43 898 Yes, n=5515 No, n=38 383 P Value
Diastolic blood pressure 80 (19) 84 (21) 79 (19) <0.0001
Respiratory rate, bpm 21 (5) 21 (5) 21 (5) 0.054
Serum lab values at admission,
median (25th, 75th percentiles)
Sodium 138 (135, 140) 138 (135 140) 138 (135, 140) <0.0001
Creatinine 1.3 (1.0, 1.8) 1.8 (1.3, 2.4) 1.3 (1.0, 1.7) <0.0001
BUN 24 (17, 36) 32 (21, 48) 23 (17, 35) <0.0001
BNP 1154 (538, 2238) 1262 (577, 2507) 1140 (534, 2160) <0.0001
Medications prior to admission (%)
Aspirin 17 904 (40.8) 2417 (43.8) 15 487 (40.3) 0.02
Beta-blockers 24 805 (56.5) 3551 (64.4) 21 254 (55.4) <0.0001
ACE inhibitors 15 280 (34.8) 1605 (29.1) 13 675 (35.6) <0.0001
ARBs 4880 (11.1) 631 (11.4) 4249 (11.1) 0.70
Aldosterone antagonists 5868 (13.4) 881 (16.0) 4987 (13.0) <0.0001
CCBs 3966 (9.0) 752 (13.6) 3214 (8.4) <0.0001
Digoxin 6994 (15.8) 924 (16.7) 6020 (15.7) 0.58
Statins 17 086 (38.9) 2388 (43.3) 14 698 (38.3) <0.0001
In-hospital procedures (%)
PCI 616 (1.6) 76 (1.6) 540 (1.7) 0.59
ICD placed 1823 (4.9) 172 (3.5) 1651 (5.1) <0.0001
Cardiac valve or CABG 321 (0.86) 18 (0.37) 303 (0.94) <0.0001
Ejection fraction (SD) 24.7 (7.8) 24.8 (7.8) 24.7 (7.8) 0.31
Days of hospital stay (median) 4.0 (2.0 to 7.0) 5.0 (3.0 to 8.0) 4.0 (2.0 to 6.0) <0.0001
SI conversion factors: to convert BUN values to millimoles per liter, multiply by 0.357; to convert creatinine values to micromoles per liter, multiply by 88.4. SD indicates standard
deviation; COPD, chronic obstructive pulmonary disease; ICD, implantable cardioverter-deﬁbrillator; CRT-D/P, cardiac synchronization therapy-deﬁbrillator/pacemaker; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass graft; BUN, blood urea nitrogen; BNP, brain-type natriuretic peptide; ACE, angiotensin-converting enzyme; ARBs, angiotenin receptor
blockers; CCBs, calcium channel blockers.
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prescription rate for H-ISDN was only 7.3% in African
American patients with HFrEF.
22 Together, these ﬁndings
suggest that the use of H-ISDN in eligible patients with HFrEF
has improved over time but still is low during hospitalization,
low in the transition from the hospital to the outpatient
setting, and low during longitudinal follow-up in outpatient
practices. The small but statistically signiﬁcant increase in the
use of H-ISDN over the study period among American
Americans could potentially be explained by participation in
the GWTG-HF quality improvement registry among other
factors.
AlthoughtheAfricanAmericanHeartFailure Trialprovedthe
effectiveness of H-ISDN in self-identiﬁed African American
patients, there has been greater uncertainty regarding the
efﬁcacyofH-ISDNinotherrace/ethnicgroups.
16Mullenet al
23
demonstrated that H-ISDN when added to ACEIs/ARBs was
associatedwithafavorablehemodynamicproﬁleandlong-term
clinical outcomes in HFrEF patients with acute decompensated
HF, regardless of race or ethnicity. However, prospective
randomized, double-blind, placebo-controlled outcome studies
with H-ISDN added to other contemporary HF therapies are
lacking in non–African American patients with HFrEF. Thus, the
usefulness of routine use of H-ISDN in non–African patients
with HFrEF is far from certain. In our study, when H-ISDN use
was stratiﬁed among different racial/ethnic groups, the
prescription of H-ISDN at the time of discharge as expected
waslowerforHispanicpatients,whitepatients,andotherrace/
ethnic groups compared with African American patients.
17,18
Chronic renal failure was identiﬁed as 1 of the most important
predictorsofH-ISDNuseamongAfricanAmericanpatientswith
HFrEF (2.33, adjusted OR, 2.02 to 2.69; P<0.0001) as well as
theoverallcohort.ThissuggeststhatH-ISDNisbeingappliedin
patients who were or are perceived to be intolerant to ACEIs. It
is also notable that patients who were prescribed H-ISDN were
less likely to receive ACEIs at discharge.
Although the prescription of H-ISDN increased over time in
GWTG-HF, its use among African American HFrEF patients
Table 2. Hospital Characteristics and Adherence to Performance and Quality Measures by Hydralazine-Isosorbide Dinitrate Use at
Hospital Discharge
Characteristics Total, n=43 898 Yes, n=5515 No, n=38 383 P Value
Hospital
Bed size, median 462 (328, 620) 527 (346, 656) 438 (311, 616) <0.0001
Academic or residents status (%) 34 095 (77.7) 4399 (79.8) 29 696 (77.4) <0.0001
Region (%)
Northeast 16 170 (36.8) 2077 (37.7) 14 093 (36.7) <0.0001
South 11 524 (26.3) 1634 (29.6) 9890 (25.8) <0.0001
Midwest 10 702 (24.4) 1285 (23.3) 9417 (24.5) <0.0001
West 5502 (12.5) 519 (9.4) 4983 (13.0) <0.0001
Interventional status (%)
PTCA 33 718 (76.8) 4374 (79.3) 29 344 (76.5) <0.0001
Surgery 30 956 (70.5) 4137 (75.0) 26 819 (69.9) <0.0001
Heart transplant capable (%) 5768 (12.9) 1188 (21.5) 4490 (11.7) <0.0001
Performance status and quality measures
Discharge instructions documented for all 6 criteria* 35 833 (93.3) 4656 (95.3) 31 177 (93) <0.0001
ACE inhibitors at discharge 31 607 (93.8) 2662 (89.0) 28 945 (94.2) <0.0001
Evidence-based beta-blockers at discharge 32 502 (79.7) 4279 (83.4) 28 223 (79.1) <0.0001
Aldosterone antagonists at discharge 12 037 (30.5) 1556 (32.8) 10 481 (29.9) <0.0001
Counseling for smoking cessation 9464 (98.8) 1199 (98.8) 8265 (98.8) 0.96
Anticoagulation for atrial fibrillation 8986 (72.7) 1019 (74.6) 7967 (72.5) 0.10
Lipid-lowering medication at discharge 20 167 (67.6) 2869 (71.2) 17 298 (67.0) <0.0001
BP control at discharge (SBP <140 and DBP <90 mm Hg) 33 800 (83.2) 3935 (74.0) 29 865 (84.6) <0.0001
ICD counseling or ICD placed or prescribed at discharge for EF <30% 12 544 (47.1) 1797 (54.1) 10 747 (46.1) <0.0001
PTCA indicates percutaneous transluminal coronary angioplasty; ACE, angiotensin-converting enzyme; SBP, systolic blood pressure; DBP, diastolic blood pressure; ICD, implantable
cardioverter-deﬁbrillator; EF, ejection fraction.
*Diet, medications, activity level, follow up appointment, weight monitoring, what to do if symptoms worsen.
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Hwas unacceptably low considering the conclusive clinical trial
evidence demonstrating substantial reductions in all-cause
mortality and hospitalizations with H-ISDN use. More impor-
tantly, our results indicate that the prescription of H-ISDN at
discharge was signiﬁcantly higher in patients already on
H-ISDN before the time of admission, whereas in patients
without prior H-ISDN, only 8.5% had this therapy initiated
during the hospitalization, and 3.6% had this therapy initiated
at the time of discharge. These data demonstrate the
reluctance to initiate H-ISDN therapy in eligible patients as
opposed to continuing the therapy in patients already on
H-ISDN. However, data with multiple drugs in both patients
with HF and patients with acute myocardial infarction
demonstrate that by far the best predictor of long-term
adherence with therapy is prescription at the time of hospital
discharge. Although there have been no speciﬁc clinical
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1
6
1
1
1
6
2
1
2
6
3
1
3
6
4
1
4
6
5
1
5
6
6
1
6
6
7
1
7
6
8
1
8
6
9
1
9
6
1
0
1
1
0
6
1
1
1
1
1
6
1
2
1
1
2
6
1
3
1
1
3
6
1
4
1
1
4
6
1
5
1
1
5
6
1
6
1
1
6
6
R
a
t
e
 
o
f
 
H
/
I
S
D
N
 
U
s
e
Hospital No.
Figure 1. Hydralazine-isosorbide dinitrate (H-ISDN) use overall in hospitals with ≥10 patients.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1
3
5
7
9
1
1
1
3
1
5
1
7
1
9
2
1
2
3
2
5
2
7
2
9
3
1
3
3
3
5
3
7
3
9
4
1
4
3
4
5
4
7
4
9
5
1
5
3
5
5
5
7
5
9
6
1
6
3
6
5
6
7
6
9
7
1
7
3
7
5
7
7
7
9
8
1
8
3
8
5
8
7
8
9
R
a
t
e
 
o
f
 
H
/
I
S
D
N
 
U
s
e
Hospital No.
Figure 2. Hydralazine-isosorbide dinitrate (H-ISDN) use in African American patients in hospitals with ≥10 self-identiﬁed African American
patients.
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Htrials performed with H-ISDN therapy among HF patients
hospitalized with HF, the cumulative clinical trials and
observational data suggest that hospitalization provides a
potential opportunity to improve adherence with this therapy.
If this cannot be achieved during the hospitalization, a
mandatory follow-up visit with instructions to consider adding
H-ISDN therapy in African American patients with HFrEF may
be warranted.
Table 3. Patterns of Hydralazine-Isosorbide Dinitrate Use (H-ISDN)
n (%)
Use in overall cohort
Patterns for patients already receiving H-ISDN before hospital admission 1818 (4.1)
Medication persisted from admission through discharge 1115 (61.3)
Medication held during hospitalization but restarted at discharge 354 (19.5)
Medication discontinued during hospitalization 211 (11.6)
Patterns for patients who did not have H-ISDN before hospital admission 42 080 (95.9)
Medication initiated during hospitalization 3578 (8.5)
Medication initiated at hospital discharge 1507 (3.6)
Use in African Americans
Patterns for patients already receiving H-ISDN before hospital admission 844 (7.6)
Medication persisted from admission through discharge 538 (63.7)
Medication held during hospitalization but restarted at discharge 176 (20.9)
Medication discontinued during hospitalization 75 (8.9)
Patterns for patients who did not have H-ISDN before hospital admission 10 341 (92.4)
Medication initiated during hospitalization 1524 (14.7)
Medication initiated at hospital discharge 675 (6.5)
H-ISDN indicates hydralazine-isosorbide dinitrate.
Table 4. Patterns of Hydralazine-Isosorbide Dinitrate Use in Patients With Documented Contraindication/Intolerance to ACEIs/
ARBs
n (%)
Use in overall cohort
Patterns for patients already receiving H-ISDN before hospital admission 898 (8.8)
Medication persisted from admission through discharge 588 (65.5)
Medication held during hospitalization but restarted at discharge 168 (18.7)
Medication discontinued during hospitalization 84 (9.4)
Patterns for patients who did not have H-ISDN before hospital admission 9297 (91.2)
Medication initiated during hospitalization 1418 (15.3)
Medication initiated at hospital discharge 608 (6.5)
Use in African Americans
Patterns for patients already receiving H-ISDN before hospital admission 309 (14.5)
Medication persisted from admission through discharge 200 (64.7)
Medication held during hospitalization but restarted at discharge 70 (22.7)
Medication discontinued during hospitalization 17 (5.5)
Patterns for patients who did not have H-ISDN before hospital admission 1821 (85.5)
Medication initiated during hospitalization 460 (25.3)
Medication initiated at hospital discharge 215 (11.8)
ACEIs indicates angiotension-converting enzyme inhibitors; ARBs, angiotension receptor blockers; H-ISDN, hydralazine-isosorbide dinitrate.
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HSlow adoption of H-ISDN use by hospitals and clinicians is
likely multifactorial. Lack of monitoring of H-ISDN use,
because it is not an HF performance measure selected by
The Joint Commission/Centers for Medicare and Medicaid
Services or the American College of Cardiology/American
Heart Association, could partially explain its limited uptake in
clinical practice. Despite a mean systolic blood pressure of
>120 mm Hg in the treatment arm of the African American
Heart Failure Trial, about 30% of the patients taking H-ISDN
reported dizziness. This along with other side effects, which
may be more prominent in the real-world population, which
tends to be older, has multiple comorbidities, and is on
polypharmacy, could also contribute to diminished use of
H-ISDN in practices. In addition, many HFrEF patients,
especially those with severely depressed ejection fraction,
tend to have low baseline blood pressure, especially when
receiving other guidelines-recommended therapy, which may
deter providers from prescribing H-ISDN because of concern
for hypotension. Three-times-a-day dosing may also affect
both prescription and adherence. Many HF patients have
erectile dysfunction and desire to use medications like
sildenaﬁl, which limits the concomitant use of nitrate therapy.
In the case of branded ﬁxed-dose combination of H-ISDN
(BiDil), cost may be an important consideration and may
explain the low use of H-ISDN in the uninsured African
Table 5. Patient and Hospital Factors Associated With
Hydralazine-Isosorbide Dinitrate Use in Overall Cohort
Variable Adjusted OR (95% CI) P Value
Age, per 10 years 0.92 (0.89 to 0.96) <0.0001
Female 0.82 (0.77 to 0.87) <0.0001
Race, African American vs white 2.24 (2.00 to 2.84) <0.0001
Race, Hispanic vs white 1.24 (1.05 to 1.46) 0.009
Medical history
Diabetes 1.27 (1.17 to 1.37) <0.0001
Hypertension 1.27 (1.13 to 1.44) 0.0001
ICD implantation 1.26 (1.15 to 1.39) <0.0001
Prior heart failure 1.27 (1.16 to 1.38) <0.0001
Anemia 1.35 (1.23 to 1.49) <0.0001
Renal insufficiency 2.56 (2.33 to 2.82) <0.0001
Chronic dialysis 0.66 (0.49 to 0.90) 0.008
Smoking 0.84 (0.78 to 0.92) <0.0001
Systolic BP, per 10 mm Hg 1.14 (1.12 to 1.16) <0.0001
Heart rate, per
10 beats/minute
0.92 (0.90 to 0.94) <0.0001
Candidate variables in the model included demographics (age, sex, race), insurance
status, medical history (atrial ﬁbrillation or ﬂutter, chronic obstructive pulmonary
disease, diabetes, dyslipidemia, hypertension, peripheral vascular disease, stroke,
implantable cardioverter deﬁbrillator implantation, previous history of heart failure,
anemia, pacemaker, dialysis, renal insufﬁciency, depression, ischemic etiology of heart
failure, smoker), vital signs (systolic BP and heart rate), hospital characteristics (region,
teaching status and number of beds). Only statistically signiﬁcant factors are reported in
the table. CI indicates conﬁdence interval; ICD, implantable cardioverter-deﬁbrillator; BP,
blood pressure.
Table 6. Patient and Hospital Factors Associated With
Hydralazine-Isosorbide Dinitrate Use in Self-Identiﬁed African
American Patients Meeting Guideline Criteria
Variable Adjusted OR (95% CI) P Value
Age, per 10 years 0.89 (0.85 to 0.94) <0.0001
Female vs male 0.77 (0.69 to 0.87) <0.0001
Insurance, uninsured
vs Medicare
0.80 (0.68 to 0.94) 0.0072
Medical history
COPD 1.18 (1.06 to 1.31) 0.0021
Diabetes 1.21 (1.07 to 1.37) 0.0021
Hypertension 1.31 (1.07 to 1.61) 0.0091
ICD implantation 1.36 (1.19 to 1.55) <0.0001
Prior heart failure 1.40 (1.23 to 1.59) <0.0001
Anemia 1.28 (1.07 to 1.52) 0.006
Chronic dialysis 0.60 (0.42 to 0.86) 0.0055
Renal insufficiency 2.31 (1.99 to 2.69) <0.0001
Smoking 0.82 (0.72 to 0.94) 0.0036
Systolic BP, per 10 mm Hg 1.15 (1.12 to 1.18) <0.0001
Heart rate, per
10 beats/minute
0.93 (0.91 to 0.95) <0.0001
Candidate variables in the model included demographics (age, sex), insurance status,
medical history (atrial ﬁbrillation or ﬂutter, chronic obstructive pulmonary disease,
diabetes, dyslipidemia, hypertension, peripheral vascular disease, stroke, implantable
cardioverter-deﬁbrillator implantation, history of heart failure, anemia, pacemaker,
dialysis, renal insufﬁciency, depression, ischemic etiology of heart failure, smoker), vital
signs (systolic BP and heart rate), hospital characteristics (region, teaching status, and
number of beds). Only statistically signiﬁcant factors are reported in the table. CI
indicates conﬁdence interval; COPD, chronic obstructive pulmonary disease; ICD,
implantable cardioverter-deﬁbrillator; BP, blood pressure.
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Figure 3. Trends in the use of hydralazine-isosorbide dinitrate
(H-ISDN) at discharge in eligible patients from 2008 to 2012.
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HAmerican population. Finally, the use of H-ISDN was signif-
icantly higher in patients also receiving other evidence-based
therapies, raising the possibility of increased compliance in
general with all therapies if further education were imparted
to providers about HF care in general. Incorporation of some
of these interventions in clinical practice, including, for
example, H-ISDN as a core performance measures, appropri-
ate documentation of contraindication of its use, further
educating primary care physicians and cardiologists, and
other interventions, might help to improve prescription
patterns with H-ISDN in clinical practice. Regardless of these
issues, there remains a substantial gap between guideline
recommendations and implementation of clinical use of
H-ISDN in African American patients with HFrEF.
Limitations
Our study has several limitations. The data collection was
dependent on the accuracy and completeness of data
abstraction from medical chart review, particularly because
eligibility for care metrics is based on documentation. In
addition, measured and unmeasured confounding factors may
have affected results. The doses of hydralazine and nitrates
that patients were discharged home on were not recorded.
We did not have information about why H-ISDN was
discontinued or not started in the absence of documented
contraindications or intolerance. This should be evaluated in
future studies. Because our data set also did not include
longitudinal follow-up, a portion of eligible patients may have
been started on H-ISDN as outpatients, underestimating its
real use. However, previous data suggest that if a medication
is not started at the time of discharge, the subsequent new
prescription rate in the outpatient setting for ACEIs and
beta-blockers is very low.
24 With the large number of patients
studied, some statistically signiﬁcant differences may be of
questionable clinical relevance and should be interpreted with
caution. Finally, GWTG-HF hospitals were self-selected and
may not be representative of all hospitals in the United
States.
Conclusions
Hydralazine-isosorbide dinitrate use in eligible African Amer-
ican patients with HFrEF remains very low in real-world
practice despite clinical trial evidence and incorporation of
these data into recommendations by multiple professional
guidelines for many years. Moreover, H-ISDN use varies
widely by hospital. Although its use has increased over time
from 2008 through 2011, it has nevertheless remained <25%,
even in African American patients with HFrEF. Given the
substantial morbidity and mortality faced by patients with
HFrEF and the established efﬁcacy of H-ISDN among African
American patients, aggressive measures to facilitate adher-
ence to H-ISDN should be sought.
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